gliclazide has been researched along with glimepiride in 55 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (10.91) | 18.2507 |
| 2000's | 13 (23.64) | 29.6817 |
| 2010's | 31 (56.36) | 24.3611 |
| 2020's | 5 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, Y; Feng, F; Guo, Q; He, S; Liu, W; Liu, Y; Sun, H; Zhao, L | 1 |
| Kume, S; Ozaki, Y; Yatomi, Y | 1 |
| Doi, K | 1 |
| Tsumura, K | 1 |
| Imamura, T; Inami, T; Ishihara, H; Ishiki, M; Iwanishi, M; Kobayashi, M; Morioka, H; Satoh, Y; Sawa, T; Takada, Y; Takata, Y; Temaru, R; Tsuda, S; Urakaze, M; Usui, I | 1 |
| Geisen, K; Krause, E; Papp, JG; Végh, A | 1 |
| Kaneko, T; Sakamoto, N | 1 |
| Brunelli, C; Cordera, R; Cordone, S; Olivotti, L; Rossettin, P; Schiavo, M; Spallarossa, P | 1 |
| Auclair, J; Bouskela, E; Félétou, M; Levens, N; Néliat, G; Ravel, D | 1 |
| Davis, KR; Dhindsa, P; Donnelly, R | 1 |
| Abe, Y; Matsumoto, K; Miyake, S; Sera, Y; Tominaga, T; Yeki, Y | 1 |
| Di Mario, U; Drzewoski, J; Grimaldi, A; Kempler, P; Kvapil, M; Novials, A; Rottiers, R; Rutten, GE; Schernthaner, G; Shaw, KM | 1 |
| Awata, T; Inukai, K; Kashiwabara, H; Katayama, S; Kurihara, S; Nakashima, Y; Sawa, T; Suzuki, M; Takata, N; Tanaka, M; Watanabe, M; Yokota, K | 1 |
| Jin, SH; Li, ZR; Shi, YQ; Yao, J | 1 |
| Kimura, T; Kita, M; Suzuma, K; Takagi, H; Watanabe, D; Yoshimura, N | 1 |
| Li, J; Wang, L; Wu, GT; Zhu, WZ | 1 |
| Fujii, M; Inoguchi, T; Kobayashi, K; Maeda, Y; Morinaga, H; Nomura, M; Sasaki, S; Sawada, F; Takayanagi, R; Tsubouchi, H | 1 |
| Argaud, L; Couture-Lepetit, E; Garrier, O; Gateau-Roesch, O; Gomez, L; Loufouat, J; Ovize, M; Robert, D | 1 |
| Khalangot, M; Kovtun, V; Kravchenko, V; Tronko, M | 1 |
| Ee, JW; Kwon, SW; Lee, J; Lee, WJ; Park, JH; Shaodong, J | 1 |
| Cheng, H; Fu, Z; Li, Y; Ran, J; Shen, J; Wang, M; Xu, L; Yan, L; Zhang, Y | 1 |
| Arai, K; Hirao, K; Kanamori, A; Matoba, K; Matsuba, I; Mori, H; Takai, M; Takeda, H; Terauchi, Y; Yamauchi, M | 1 |
| Chen, Y; Hu, YY; Wu, FZ; Ye, SD; Zhao, LL; Zheng, M | 1 |
| Abdelmoneim, AS; Brocks, DR; Hasenbank, SE; Light, PE; Seubert, JM; Simpson, SH | 1 |
| Jermendy, G | 1 |
| Fatehi, M; Lang, VY; Light, PE | 1 |
| Manolopoulos, VG; Petridis, I; Ragia, G; Tavridou, A | 1 |
| Dyrskjøt, L; Grimm, D; Magnusson, NE; Pietsch, J; Rungby, J; Wehland, M | 1 |
| Kimura, H; Masuda, S; Sato, D; Sato, Y | 1 |
| Agrawal, N; Bhandari, S; Chandurkar, N; Deshpande, A; Devaramani, S; Gupta, OP; Kakrani, A; Kothari, K; Mahesh, M; Pareek, A; Saboo, B; Shah, A; Sharma, S; Thomas, N; Thulasidharan, NK; Vijaykumar, NB; Viswanathan, V | 1 |
| Fernandes, C; Lima, Pde P; Soares, CD; Viana, IM | 1 |
| Andersson, C; Fosbøl, EL; Gislason, G; Køber, L; Mogensen, UM; Scheller, NM; Schramm, TK; Torp-Pedersen, C; Vaag, A | 1 |
| Ahn, CW; Balkau, B; Cha, BS; Choe, EY; Kang, ES; Lee, BW; Lee, CJ; Lee, HC; Lee, HS; Lee, YH | 1 |
| Winkler, G | 1 |
| Abd-Allah, GM; Hassan, MH | 1 |
| Chen, GM; Lu, J; Shao, H; Xu, YT; Zhan, Y; Zhang, HJ | 1 |
| Alam, F; Gan, SH; Islam, MA; Kamal, MA | 1 |
| Bilo, H; Bouma, A; Groenier, KH; Kleefstra, N; Landman, GW; van Dijk, P; van Hateren, KJ | 1 |
| Bi, Y; Engel, SS; Ji, L; Ji, Q; Jia, W; Lu, J; Mao, A; Mu, Y; Ran, X; Weng, J; Xu, W; Yang, W; Yao, B; Zeng, L; Zhao, B; Zhao, J; Zhou, Z; Zhu, D | 1 |
| Cha, BS; Kang, ES; Kim, G; Lee, BW; Lee, JY; Lee, YH; Nam, CM | 1 |
| Algeelani, S; Alkhelb, D; Greenblatt, DJ | 1 |
| Bien, Z; Heald, AH; Laing, I; Livingston, M; Moreno, GYC; Stedman, M | 1 |
| Dong, J; Liao, L; Shen, X; Xie, T; Xu, C; Zhang, R; Zhou, X; Zou, Z | 1 |
| Huang, HK; Yeh, JI | 1 |
| Jang, SY; Kang, ES; Lee, JY; Nam, CM | 1 |
| Cao, J; Jiang, Q; Li, H; Li, R; Xu, Q | 1 |
| Cho, EH; Han, K; Kim, B; Lee, DH | 1 |
| Chiriac, FL; Iancu, VI; Radu, GL; Scutariu, RE | 1 |
| Gayakvad, B; Kothari, C; Patel, C; Patel, R; Solanki, R; Wadhwana, P | 1 |
| Alejandro-Ribaya, EL; Aman, AYC; Añonuevo-Cruz, C; Bernardo, DC; Biwang, J; Calpito, KJA; Deguit, CD; Ferrer, JP; Francisco, MD; Guanzon, MLV; Jaring, C; Jasul, G; Lat, AM; Maningat, MPD; Mansibang, NM; Melegrito, J; Nacpil-Dominguez, P; Nevado, J; Pala-Mohamad, A; Panerio, CE; Paz, EMC; Paz-Pacheco, E; Quisumbing, JP; Ribaya, VS; Uy-Canto, A; Uyking-Naranjo, M | 1 |
6 review(s) available for gliclazide and glimepiride
| Article | Year |
|---|---|
Overview of AKR1C3: Inhibitor Achievements and Disease Insights.
Topics: Aldo-Keto Reductase Family 1 Member C3; Antineoplastic Agents; Binding Sites; Cell Proliferation; Clinical Trials as Topic; Drug Development; Drug Resistance, Neoplasm; Humans; Models, Molecular; Molecular Structure; Neoplasms; Treatment Outcome | 2020 |
[Clinical efficacy of glimepiride].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Gliclazide; Glyburide; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Sulfonylurea Compounds; Vascular Resistance | 1997 |
Variations in tissue selectivity amongst insulin secretagogues: a systematic review.
Topics: Animals; ATP-Binding Cassette Transporters; Carbamates; Cardiovascular Diseases; Cricetinae; Cyclohexanes; Diabetes Mellitus, Type 2; Gliclazide; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Ischemic Preconditioning, Myocardial; Isoindoles; Mice; Muscle, Smooth, Vascular; Myocytes, Cardiac; Nateglinide; Phenylalanine; Piperidines; Potassium Channels, Inwardly Rectifying; Rats; Receptors, Drug; Risk Factors; Sulfonylurea Compounds; Sulfonylurea Receptors; Tolbutamide | 2012 |
[Incretin-based therapy for treating patients with type 2 diabetes].
Topics: Adamantane; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Therapy, Combination; Exenatide; Gliclazide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hungary; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Metformin; Nitriles; Peptides; Pioglitazone; Purines; Pyrazines; Pyrrolidines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Venoms; Vildagliptin | 2011 |
[Sulfonylureas in today's blood glucose lowering therapy. New data on advantages and potential barriers of an "old" antidiabetic group].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Gliclazide; Humans; Hungary; Hypoglycemic Agents; Incretins; Insulin; Sulfonylurea Compounds | 2015 |
Updates on Managing Type 2 Diabetes Mellitus with Natural Products: Towards Antidiabetic Drug Development.
Topics: Biological Products; Diabetes Mellitus, Type 2; Drug Discovery; Gliclazide; Glucose Transporter Type 4; Humans; Hypoglycemic Agents; Metformin; Oxidative Stress; Sulfonylurea Compounds | 2018 |
13 trial(s) available for gliclazide and glimepiride
| Article | Year |
|---|---|
Clinical evaluation of glimepiride (HOE490) in NIDDM, including a double blind comparative study versus gliclazide.
Topics: Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Sulfonylurea Compounds | 1995 |
Sulfonylurea treatment of type 2 diabetic patients does not reduce the vasodilator response to ischemia.
Topics: Aged; Aged, 80 and over; Blood Pressure; Brachial Artery; Diabetes Mellitus, Type 2; Diet, Diabetic; Female; Forearm; Gliclazide; Glyburide; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Ischemia; Male; Metformin; Middle Aged; Reference Values; Regional Blood Flow; Sulfonylurea Compounds; Ultrasonography | 2001 |
Comparison of the micro- and macro-vascular effects of glimepiride and gliclazide in metformin-treated patients with Type 2 diabetes: a double-blind, crossover study.
Topics: Aged; Cross-Over Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Gliclazide; Humans; Hypoglycemic Agents; Metformin; Microcirculation; Middle Aged; Sulfonylurea Compounds; Vasodilation | 2003 |
GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Sulfonylurea Compounds; Treatment Outcome | 2004 |
Efficacy of glimepiride in Japanese type 2 diabetic subjects.
Topics: Aged; Asian People; Body Mass Index; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Gliclazide; Glyburide; Glycated Hemoglobin; Homeostasis; Humans; Hypoglycemic Agents; Insulin Resistance; Logistic Models; Male; Middle Aged; Obesity; Retreatment; Sulfonylurea Compounds; Treatment Outcome | 2005 |
Effects of short-term therapy with different insulin secretagogues on glucose metabolism, lipid parameters and oxidative stress in newly diagnosed Type 2 Diabetes Mellitus.
Topics: Adult; Aged; Analysis of Variance; Blood Glucose; Carbamates; Chi-Square Distribution; Diabetes Mellitus, Type 2; Female; Fructosamine; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipid Peroxidation; Lipids; Male; Middle Aged; Oxidative Stress; Piperidines; Postprandial Period; Sulfonylurea Compounds; Treatment Outcome | 2010 |
Hydrochloride pioglitazone decreases urinary cytokines excretion in type 2 diabetes.
Topics: Adult; Albuminuria; Blood Glucose; Blood Pressure; Chemokine CCL2; Creatinine; Cytokines; Diabetes Mellitus, Type 2; Enzyme-Linked Immunosorbent Assay; Female; Gliclazide; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Transforming Growth Factor beta1; Vascular Endothelial Growth Factor A | 2010 |
Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone.
Topics: Adolescent; Adult; Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Gliclazide; Glycated Hemoglobin; Humans; Hydroxychloroquine; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Young Adult | 2014 |
Simultaneous determination of oral antidiabetic drugs in human plasma using microextraction by packed sorbent and high-performance liquid chromatography.
Topics: Chlorpropamide; Chromatography, High Pressure Liquid; Gliclazide; Humans; Hydrogen-Ion Concentration; Hypoglycemic Agents; Reproducibility of Results; Solid Phase Microextraction; Sulfonylurea Compounds | 2014 |
Effects of metformin plus gliclazide versus metformin plus glimepiride on cardiovascular risk factors in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Folic Acid; Gliclazide; Glycated Hemoglobin; Homocysteine; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Risk Factors; Sulfonylurea Compounds | 2015 |
Hypoglycemia in Frail Elderly Patients With Type 2 Diabetes Mellitus Treated With Sulfonylurea.
Topics: Aged; Aged, 80 and over; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Female; Frail Elderly; Gliclazide; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Sulfonylurea Compounds | 2017 |
Efficacy and safety of metformin and sitagliptin based triple antihyperglycemic therapy (STRATEGY): a multicenter, randomized, controlled, non-inferiority clinical trial.
Topics: Acarbose; Adult; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Piperidines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome | 2017 |
Incident Hepatocellular Carcinoma Risk in Patients Treated with a Sulfonylurea: A Nationwide, Nested, Case-Control Study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Incidence; Liver Neoplasms; Male; Middle Aged; Republic of Korea; Risk Factors; Sulfonylurea Compounds | 2019 |
36 other study(ies) available for gliclazide and glimepiride
| Article | Year |
|---|---|
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Effects of oral hypoglycaemic agents on platelet functions.
Topics: Arachidonic Acid; Calcium; Dose-Response Relationship, Drug; Fura-2; Gliclazide; Glyburide; Humans; Ionomycin; Platelet Activation; Platelet Aggregation Inhibitors; Sulfonylurea Compounds | 1992 |
[New oral antidiabetic agents].
Topics: Animals; Cyclohexanols; Diabetes Mellitus; Drug Evaluation; Gliclazide; Glyburide; Humans; Hypoglycemic Agents; Imidazoles; Insulin; Insulin Secretion; Molecular Structure; Pyrrolidines; Stimulation, Chemical; Sulfonylurea Compounds | 1990 |
Effect of glimepiride (HOE 490) on insulin receptors of skeletal muscles from genetically diabetic KK-Ay mouse.
Topics: Animals; Diabetes Mellitus, Experimental; Diglycerides; Gliclazide; Hypoglycemic Agents; Insulin; Male; Mice; Muscle, Skeletal; Phosphorylation; Protein-Tyrosine Kinases; Receptor, Insulin; Sulfonylurea Compounds | 1996 |
Cardiovascular effects of conventional sulfonylureas and glimepiride.
Topics: Animals; Blood Pressure; Cardiovascular System; Coronary Vessels; Diabetes Mellitus, Experimental; Dogs; Electrocardiography; Female; Gliclazide; Glyburide; Hypoglycemic Agents; Male; Myocardial Ischemia; Potassium Channels; Rats; Rats, Wistar; Sulfonylurea Compounds | 1996 |
Differential effects of sulphonylureas on the vasodilatory response evoked by K(ATP) channel openers.
Topics: Adenosine Triphosphate; Animals; Aorta, Thoracic; Cricetinae; Cromakalim; Diazoxide; Drug Interactions; Gliclazide; Glyburide; Guinea Pigs; Hypoglycemic Agents; In Vitro Techniques; Ion Channel Gating; Male; Potassium Channels; Rats; Rats, Wistar; Species Specificity; Sulfonylurea Compounds; Vasodilation; Vasodilator Agents | 2003 |
Metformin attenuates progression of carotid arterial wall thickness in patients with type 2 diabetes.
Topics: Arteriosclerosis; Carotid Arteries; Carotid Artery Diseases; Chronic Disease; Diabetes Mellitus, Type 2; Diet Therapy; Drug Administration Schedule; Female; Gliclazide; Glyburide; Glycated Hemoglobin; Humans; Japan; Male; Metformin; Middle Aged; Prospective Studies; Sulfonylurea Compounds; Time Factors; Tunica Intima; Tunica Media | 2004 |
Development of a RP-HPLC method for screening potentially counterfeit anti-diabetic drugs.
Topics: Carbamates; Chromatography, High Pressure Liquid; Gliclazide; Glipizide; Glyburide; Hypoglycemic Agents; Molecular Structure; Piperidines; Reproducibility of Results; Sulfonylurea Compounds | 2007 |
Comparisons between the beneficial effects of different sulphonylurea treatments on ischemia-induced retinal neovascularization.
Topics: Acetylcysteine; Animals; Blood Glucose; Female; Gliclazide; Glyburide; Ischemia; Mice; Oxidative Stress; Oxygen; Retina; Retinal Neovascularization; RNA, Messenger; Sulfonylurea Compounds; Vascular Endothelial Growth Factor A | 2007 |
Effects of glibenclamide, glimepiride, and gliclazide on ischemic preconditioning in rat heart.
Topics: Animals; Gliclazide; Glyburide; Heart; Ischemic Preconditioning; Male; Rats; Rats, Sprague-Dawley; Sulfonylurea Compounds | 2007 |
Differential effect of sulfonylureas on production of reactive oxygen species and apoptosis in cultured pancreatic beta-cell line, MIN6.
Topics: Animals; Apoptosis; Cell Line; Cyclohexanes; Fluoresceins; Gliclazide; Glyburide; Hypoglycemic Agents; In Situ Nick-End Labeling; Insulin-Secreting Cells; Mice; Mice, Inbred C57BL; Microscopy, Fluorescence; NADPH Oxidases; Nateglinide; Phenylalanine; Protein Kinase C; Reactive Oxygen Species; Sulfonylurea Compounds | 2008 |
Second-generation sulfonylureas preserve inhibition of mitochondrial permeability transition by the mitochondrial K+(ATP) opener nicorandil in experimental myocardial infarction.
Topics: Animals; Calcium; Gliclazide; Glyburide; Hemodynamics; Male; Mitochondria; Myocardial Infarction; Nicorandil; Potassium Channel Blockers; Potassium Channels; Rabbits; Sulfonylurea Compounds | 2009 |
Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study.
Topics: Blood Glucose; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Cohort Studies; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Gliclazide; Glyburide; Humans; Hypoglycemic Agents; Middle Aged; Patient Selection; Proportional Hazards Models; Risk Factors; Sulfonylurea Compounds; Ukraine | 2009 |
Comparison of ultraviolet detection, evaporative light scattering detection and charged aerosol detection methods for liquid-chromatographic determination of anti-diabetic drugs.
Topics: Aerosols; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Gliclazide; Glipizide; Glyburide; Hypoglycemic Agents; Light; Reproducibility of Results; Scattering, Radiation; Spectrophotometry, Ultraviolet; Sulfonylurea Compounds | 2010 |
Present status of sulfonylurea treatment for type 2 diabetes in Japan: second report of a cross-sectional survey of 15,652 patients.
Topics: Aged; Blood Glucose; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Family Practice; Gliclazide; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Middle Aged; Practice Patterns, Physicians'; Sulfonylurea Compounds; Treatment Outcome | 2010 |
Pharmacogenomic analysis of ATP-sensitive potassium channels coexpressing the common type 2 diabetes risk variants E23K and S1369A.
Topics: ATP-Binding Cassette Transporters; Chlorpropamide; Cyclohexanes; Diabetes Mellitus, Type 2; Gene Expression Regulation; Gliclazide; Glyburide; Haplotypes; Homozygote; Humans; Isoindoles; Nateglinide; Patch-Clamp Techniques; Phenylalanine; Polymorphism, Single Nucleotide; Potassium Channels, Inwardly Rectifying; Receptors, Drug; Structure-Activity Relationship; Sulfonylurea Compounds; Sulfonylurea Receptors; Tolbutamide | 2012 |
Association of KCNJ11 E23K gene polymorphism with hypoglycemia in sulfonylurea-treated type 2 diabetic patients.
Topics: Adult; Aged; Alleles; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C9; Diabetes Mellitus, Type 2; Female; Genotype; Gliclazide; Glutamic Acid; Glycated Hemoglobin; Greece; Humans; Hypoglycemia; Lysine; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Genetic; Potassium Channels, Inwardly Rectifying; Sulfonylurea Compounds | 2012 |
Gene networks modified by sulphonylureas in beta cells: a pathway-based analysis of insulin secretion and cell death.
Topics: Animals; Cell Death; Cell Line; Cluster Analysis; Diabetes Mellitus, Type 2; Gene Regulatory Networks; Gliclazide; Glyburide; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Microarray Analysis; Rats; Sulfonylurea Compounds; Up-Regulation | 2012 |
Effects of a sitagliptin safety alert on prescription behaviour for oral antihyperglycaemic drugs: a propensity score-matched cohort study of prescription receipt data in Japan.
Topics: Aged; Cohort Studies; Female; Gliclazide; Glyburide; Humans; Hypoglycemic Agents; Japan; Logistic Models; Male; Middle Aged; Patient Safety; Practice Patterns, Physicians'; Propensity Score; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles | 2013 |
Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study.
Topics: Aged; Carbamates; Cardiovascular Diseases; Denmark; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gliclazide; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Morbidity; Myocardial Infarction; Piperidines; Registries; Retrospective Studies; Risk Factors; Stroke; Sulfonylurea Compounds; Tolbutamide | 2015 |
Comparing kidney outcomes in type 2 diabetes treated with different sulphonylureas in real-life clinical practice.
Topics: Cohort Studies; Creatinine; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Kidney Failure, Chronic; Male; Middle Aged; Propensity Score; Retrospective Studies; Sulfonylurea Compounds | 2015 |
Metabolic Interaction Potential between Clopidogrel and Sulfonylurea Antidiabetic Agents: Effects on Clopidogrel Bioactivation.
Topics: Carboxylic Ester Hydrolases; Clopidogrel; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9 Inhibitors; Dose-Response Relationship, Drug; Drug Antagonism; Gliclazide; Glipizide; Humans; Hypoglycemic Agents; Intestines; Liver; Microsomes; Sulfonylurea Compounds; Ticlopidine | 2016 |
Comparison of hepatocellular carcinoma risk between patients treated with glimepiride and gliclazide.
Topics: Aged; Carcinoma, Hepatocellular; Female; Gliclazide; Humans; Hypoglycemic Agents; Incidence; Liver Neoplasms; Male; Middle Aged; Risk; Sulfonylurea Compounds | 2019 |
Inhibitory effects of sulfonylureas and non-steroidal anti-inflammatory drugs on in vitro metabolism of canagliflozin in human liver microsomes.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Canagliflozin; Chlorpropamide; Diclofenac; Dose-Response Relationship, Drug; Drug Interactions; Gliclazide; Humans; Hypoglycemic Agents; Microsomes, Liver; Niflumic Acid; Sulfonylurea Compounds | 2018 |
The pattern of prescribing of glucose modulating agents for type 2 diabetes in general practices in England 2016/17.
Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Costs; Drug Prescriptions; England; Exenatide; General Practice; Gliclazide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Peptides; Practice Patterns, Physicians'; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Venoms | 2018 |
Different sulfonylureas induce the apoptosis of proximal tubular epithelial cell differently via closing K
Topics: Apoptosis; Cell Line; Epithelial Cells; Gliclazide; Glyburide; Humans; KATP Channels; Kidney Tubules, Proximal; Sulfonylurea Compounds | 2018 |
Comparison of mortality and cardiovascular event risk associated with various insulin secretagogues: A nationwide real-world analysis.
Topics: Aged; Carbamates; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gliclazide; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Middle Aged; Mortality; Piperidines; Secretagogues; Sulfonylurea Compounds; Taiwan | 2019 |
Nanofibers mat as sampling module of direct analysis in real time mass spectrometry for sensitive and high-throughput screening of illegally adulterated sulfonylureas in antidiabetic health-care teas.
Topics: Acrylic Resins; Allyl Compounds; Food Contamination; Gliclazide; Hypoglycemic Agents; Imidazoles; Ionic Liquids; Mass Spectrometry; Nanofibers; Solid Phase Extraction; Sulfonylurea Compounds; Tea | 2019 |
Gliclazide monotherapy increases risks of all-cause mortality and has similar risk of acute myocardial infarction and stroke with glimepiride monotherapy in Korean type 2 diabetes mellitus.
Topics: Adult; Aged; Asian People; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Myocardial Infarction; Republic of Korea; Risk Factors; Stroke; Sulfonylurea Compounds | 2020 |
Sensitive detection of antidiabetic compounds and one degradation product in wastewater samples by a new SPE-LC-MS/MS method.
Topics: Chromatography, Liquid; Environmental Monitoring; Gliclazide; Glipizide; Glyburide; Hypoglycemic Agents; Metformin; Reproducibility of Results; Solid Phase Extraction; Sulfonylurea Compounds; Tandem Mass Spectrometry; Wastewater; Water Pollutants, Chemical | 2021 |
Analytical Method Capable of Quantifying Eight Nitrosamine Impurities from Five Different Commercially Available Metformin Formulations with Glipizide, Glibenclamide, Gliclazide, Evogliptin, and Glimepiride by Ultra High Performance Liquid Chromatography
Topics: Chromatography, High Pressure Liquid; Chromatography, Liquid; Diabetes Mellitus, Type 2; Gliclazide; Glipizide; Glyburide; Humans; Metformin; Nitrosamines; Pharmaceutical Preparations; Tandem Mass Spectrometry | 2023 |
Genetic Variants Associated with Poor Responsiveness to Sulfonylureas in Filipinos with Type 2 Diabetes Mellitus.
Topics: Diabetes Mellitus, Type 2; Gliclazide; Humans; Hypoglycemic Agents; Sulfonylurea Compounds | 2023 |